| __timestamp | Iovance Biotherapeutics, Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 9335772 | 179279000 |
| Thursday, January 1, 2015 | 999000 | 186359000 |
| Friday, January 1, 2016 | 978000 | 171785000 |
| Sunday, January 1, 2017 | 952000 | 208136000 |
| Monday, January 1, 2018 | 956000 | 198405000 |
| Tuesday, January 1, 2019 | 8122999 | 224169000 |
| Wednesday, January 1, 2020 | 8712000 | 245044000 |
| Friday, January 1, 2021 | 13980000 | 252314000 |
| Saturday, January 1, 2022 | 21135000 | 268225000 |
| Sunday, January 1, 2023 | 10755000 | 304629000 |
| Monday, January 1, 2024 | 324203000 |
In pursuit of knowledge
In the competitive landscape of pharmaceuticals, cost efficiency is paramount. Iovance Biotherapeutics, Inc. and Taro Pharmaceutical Industries Ltd. present a fascinating study in contrasts. Over the past decade, Taro has consistently maintained a robust cost of revenue, averaging around $232 million annually. This reflects a stable operational efficiency, crucial for sustaining its market position. In contrast, Iovance's cost of revenue has seen a more volatile trajectory, with a significant increase of over 100% from 2014 to 2023. This could indicate strategic investments in research and development, a common trend among biotech firms aiming for innovation. Notably, Taro's cost of revenue in 2023 surged by approximately 14% compared to the previous year, hinting at potential expansion or increased production costs. As we look to the future, the missing data for 2024 leaves room for speculation on how these companies will navigate the ever-evolving pharmaceutical landscape.
Cost of Revenue Comparison: AstraZeneca PLC vs Taro Pharmaceutical Industries Ltd.
Cost Insights: Breaking Down Pfizer Inc. and Taro Pharmaceutical Industries Ltd.'s Expenses
Cost of Revenue: Key Insights for GSK plc and Iovance Biotherapeutics, Inc.
Cost Insights: Breaking Down BeiGene, Ltd. and Iovance Biotherapeutics, Inc.'s Expenses
Cost of Revenue Comparison: Catalent, Inc. vs Iovance Biotherapeutics, Inc.
Cost of Revenue Trends: Halozyme Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.
Analyzing Cost of Revenue: CRISPR Therapeutics AG and Iovance Biotherapeutics, Inc.
Cost of Revenue: Key Insights for Xenon Pharmaceuticals Inc. and Iovance Biotherapeutics, Inc.
Xenon Pharmaceuticals Inc. vs Taro Pharmaceutical Industries Ltd.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: MorphoSys AG vs Taro Pharmaceutical Industries Ltd.
Cost Insights: Breaking Down Taro Pharmaceutical Industries Ltd. and Dyne Therapeutics, Inc.'s Expenses
Cost of Revenue Trends: Taro Pharmaceutical Industries Ltd. vs Celldex Therapeutics, Inc.